Item 7.01 Regulation FD Disclosure.

On April 12, 2023, MyMD Pharmaceuticals, Inc. (the "Company") issued a press release describing developments in the Phase 2 clinical trial of its MYMD-1® product candidate for sarcopenia and frailty. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Also furnished herewith as Exhibit 99.2 to this Current Report on Form 8-K is a slide presentation that the Company intends, from time to time, to present and/or distribute to the investment community and utilize at various industry and other conferences. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1 and Exhibit 99.2.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit Number   Description

99.1               Press Release, dated April 12, 2023 (furnished herewith
                 pursuant to Item 7.01)
99.2               Corporate Presentation, dated April 2023 (furnished herewith
                 pursuant to Item 7.01)
104              Cover Page Interactive Data File (formatted as Inline XBRL)

© Edgar Online, source Glimpses